Grant: Engage Grants Program
University of Alberta
$25,000.00
Development of a novel gene delivery method using nanodarts
EF 2010-11
Résumé
Existing methods of gene delivery, including microinjection, gene guns, electroporation, sonoporation,
magnetofection, calcium phosphate, viral delivery, and liposomal delivery, are limited in their success due to
low transfection / transform efficiency, insufficient permeability across cell membranes / walls, and various
safety concerns. Nanotechnology, with its focus on creating nanomaterials ranging 10nm to 100nm in size, can
provide novel solutions to these problems. Under the leadership of the principal investigator, a research team
at the University of Alberta has invented a novel nanodart technology aiming to improve gene delivery
efficiency. They have successfully delivered biomolecules (such as ""FITC"") and DNA plasmids (including
""GFP"") into mammalian cells with a success rate significantly higher than existing delivery methods. A
worldwide PCT patent has been filed, several papers have been published in influential peer-reviewed journals
(such as Journal of Nanotechnology), and the discovery was presented at international conferences (including
the annual conference of the International Society for Cellular Therapy).
A local biotechnology company, ATGCell Inc. in Edmonton, specializes in recombinant protein expression and
purification using animal cells. Current viral and lipid-based transfection reagents, such as lipofectamine from
Invitrogen, are not effective. An efficient in-vitro gene delivery technique is needed for their R&D and custom
projects. To translate cutting edge laboratory research into industrial practice, the UofA team and ATGCell will
form a strategic alliance to apply the newly developed nanodart technology to solve the company's specific
gene delivery challenges. During this 6-month project, ATGCell will provide DNA plasmids and siRNA for
the UofA team to link onto nanodarts using surface modification techniques. Both teams will check the cell
expression and transfection rate, as well as compare transfection results with current methods used by ATGCell
and established industry standards.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
401567-2010
Name nom
Chen, Jie
Department département
Biomedical Engineering
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2010
Competition year année de concours
2010
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1555
Committee name en
Prairie Internal Decision Committee
Committee name fr
Comité de décision interne pour les Prairies
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Partie
1
Nb partie
1
Application title
Development of a novel gene delivery method using nanodarts
Keyword
NSERC
Application summary
Existing methods of gene delivery, including microinjection, gene guns, electroporation, sonoporation,
magnetofection, calcium phosphate, viral delivery, and liposomal delivery, are limited in their success due to
low transfection / transform efficiency, insufficient permeability across cell membranes / walls, and various
safety concerns. Nanotechnology, with its focus on creating nanomaterials ranging 10nm to 100nm in size, can
provide novel solutions to these problems. Under the leadership of the principal investigator, a research team
at the University of Alberta has invented a novel nanodart technology aiming to improve gene delivery
efficiency. They have successfully delivered biomolecules (such as ""FITC"") and DNA plasmids (including
""GFP"") into mammalian cells with a success rate significantly higher than existing delivery methods. A
worldwide PCT patent has been filed, several papers have been published in influential peer-reviewed journals
(such as Journal of Nanotechnology), and the discovery was presented at international conferences (including
the annual conference of the International Society for Cellular Therapy).
A local biotechnology company, ATGCell Inc. in Edmonton, specializes in recombinant protein expression and
purification using animal cells. Current viral and lipid-based transfection reagents, such as lipofectamine from
Invitrogen, are not effective. An efficient in-vitro gene delivery technique is needed for their R&D and custom
projects. To translate cutting edge laboratory research into industrial practice, the UofA team and ATGCell will
form a strategic alliance to apply the newly developed nanodart technology to solve the company's specific
gene delivery challenges. During this 6-month project, ATGCell will provide DNA plasmids and siRNA for
the UofA team to link onto nanodarts using surface modification techniques. Both teams will check the cell
expression and transfection rate, as well as compare transfection results with current methods used by ATGCell
and established industry standards.